VRBPAC Votes To Endorse mRNA Influenza Vaccine Prasad Blocked

Why It Matters

The endorsement accelerates the path to market for the first mRNA flu vaccine, promising quicker strain updates and stronger protection for high‑risk seniors, which could shift the seasonal influenza landscape.

Key Takeaways

• VRBPAC unanimously backs Moderna's mFlusiva for seniors
• Targets adults aged 50‑64 and 65+
• mRNA platform may speed seasonal flu vaccine updates
• Could shift market share from traditional egg‑based vaccines
• Endorsement may accelerate FDA approval and distribution

Pulse Analysis

The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously on June 18 to endorse Moderna’s mRNA influenza vaccine, mFlusiva, for adults 50‑64 and those 65 and older. The advisory panel concluded that the clinical data demonstrate a favorable benefit‑risk profile, marking the first time an mRNA‑based flu shot has received formal endorsement from the agency. VRBPAC’s recommendation is a key step toward full FDA licensure, which could bring the product to market ahead of the 2027 flu season.

If approved, mFlusiva could reshape the seasonal flu market that has long been dominated by egg‑based vaccines. The mRNA platform allows manufacturers to update the antigen composition within weeks, a speed advantage that proved critical during the COVID‑19 pandemic. Health systems may see higher vaccine effectiveness, especially in older adults who experience the highest morbidity and mortality from influenza. Moreover, the entry of a novel technology could spur competition, potentially driving down prices and expanding access.

Regulators will still need to review the full Biologics License Application, but the advisory committee’s endorsement typically shortens the review timeline. Payers will scrutinize cost‑effectiveness, as mRNA vaccines often carry higher manufacturing expenses than traditional flu shots. Nevertheless, the promise of improved efficacy and rapid strain adaptation may justify premium pricing, especially for Medicare beneficiaries. Industry observers expect other manufacturers to accelerate their own mRNA flu candidates, intensifying the race for the next generation of influenza prevention.